For research use only. Not for therapeutic Use.
Potent P-gp inhibitor with good selectivity towards BCRP pump (EC50 values 0.05 μM, 0.69 μM, 9.3 μM, and 73 μM for Caco-2, MDR1, MRP1, and BCRP inhibition, respectively), with potential as novel anticancer agent with both cytostatic and cytotoxic characteristics. MC70, as an inhibitor of the ABC transporter ABCB1 (aka MDR1), potentiates Doxorubicin efficacy in colon and breast cancer in vitro treatment.
*Sold in collaboration with Biofordrug srl
KEYWORDS: MC70 hydrochloride | supplier | P-gp inhibitor | MC-70 | MC 70 | CAS [2108830-71-1] | [1031367-64-2] | PGP | ABC transporter | ABCB1 | MDR1 | BCRP | Caco-2 | breast cancer | Non Selective | P-glycoprotein | Inhibitor | Proteins
| Catalog Number | I031648 |
| CAS Number | 2108830-71-1 |
| Molecular Formula | C24H25NO3.HCl |
| Purity | ≥95% |
| IUPAC Name | 4-[4-[(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)methyl]phenyl]phenol;hydrochloride |
| InChI | InChI=1S/C24H25NO3.ClH/c1-27-23-13-20-11-12-25(16-21(20)14-24(23)28-2)15-17-3-5-18(6-4-17)19-7-9-22(26)10-8-19;/h3-10,13-14,26H,11-12,15-16H2,1-2H3;1H |
| SMILES | COC1=C(C=C2CN(CCC2=C1)CC3=CC=C(C=C3)C4=CC=C(C=C4)O)OC.Cl |
| Reference | S Guglielmo et al. A potent and selective P-gp modulator for altering multidrug resistance due to pump overexpression. ChemMedChem. 2016 Feb 17;11(4):374-6.
A Azzariti et al. MC70 potentiates doxorubicin efficacy in colon and breast cancer in vitro treatment. Eur J Pharmacol. 2011 Nov 16;670(1):74-84.
NA Colabufo et al. 4-Biphenyl and 2-naphthyl substituted 6,7-dimethoxytetrahydroisoquinoline derivatives as potent P-gp modulators. Bioorg Med Chem. 2008 Apr 1;16(7):3732-43.
NA Colabufo et al. Multi-drug-resistance-reverting agents: 2-aryloxazole and 2-arylthiazole derivatives as potent BCRP or MRP1 inhibitors. ChemMedChem. 2009 Feb;4(2):188-95. |
